Platelet-activating factor antagonism improves ventricular contractility in endotoxemia

Critical Care Medicine

Volumn 25, Issue 2, 1997, Pages 221-226

  Herbertson, Michael J ^a   Werner, Heinrich A ^a,b   Walley, Keith R ^a,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Heart and Stroke Foundation of British Columbia and Yukon   (United Kingdom)

^c HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

Author keywords

left ventricular contractility; platelet activating factor receptor antagonism; septic shock

Indexed keywords

2 (3 METHOXY 5 METHYLSULFONYL 4 PROPOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTOXEMIA; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE CONTRACTILITY; HEMODYNAMICS; HYPOTENSION; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SWINE; THROMBOCYTE ACTIVATION;

ANIMALS; ENDOTOXEMIA; ENDOTOXINS; FURANS; HEART VENTRICLES; HEMODYNAMIC PROCESSES; MYOCARDIAL CONTRACTION; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SWINE;

EID: 0031019915     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199702000-00004     Document Type: Article

References (42)

1. Parker MM, Suffredini AF, Natanson C, et al: Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 1989; 4: 19-25
2. Natanson C, Fink MP, Ballantyne HK, et al: Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986; 78:259-270
3. Diez FL, Nieto ML, Fernandez-Gallardo S, et al: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83:1733-1740
4. Graham RM, Stephens CJ, Silvester W, et al: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22:204-212
5. Goldstein RE, Ezra D, Laurindo FRM, et al: Coronary and pulmonary vascular effects of leukotrienes and PAF-acether. Pharmacol Res Commun 1986; 18:151-162
6. Sybertz EJ, Watkins RW, Baum T, et al: Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anesthetized dog. J Pharmacol Exp Ther 1985; 232: 156-162
7. Alloatti G, Montrucchio G, Mariano F, et al: Effects of platelet-activating factor (PAF) on human cardiac muscle. Int Arch Allergy Appl Immmunol 1986; 79:108-112
8. Adnot S, Lefort J, Lagente V, et al: Interference of BN 52021, a PAF-acether antagonist with endotoxin-induced hypotension in the guinea-pig. Pharmacol Res Commun 1986; 18: 197-200
9. Walley KR, Hebert PC, Wakai Y, et al: Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol 1994; 76: 1060-1067
10. Walley KR: Ventricular dysfunction in sepsis. In: Yearbook of Intensive Care and Emergency Medicine. Vincent J-L (Ed). New York, Berlin, Springer-Verlag, 1995, pp 505-517
11. Soulsby ME, Jacobs ER, Perlmutter BH, et al: Protection of myocardial function during endotoxin shock by ibuprofen. Prostaglandins Leukot Med 1984; 13: 295-305
12. Stahl GL, Bitterman H, Lefer AM: Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. Thromb Res 1989; 53:327-338
13. Lefer AM: Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: Relevance to multiple systems organ failure. Crit Care Clin 1989; 5:331-352
14. Kass DA, Maughan WL, Guo ZM, et al: Comparative influence of load versus inotropic states on indexes of ventricular contractility: Experimental and theoretical analysis based on pressure-volume relationships. Circulation 1987; 76:1422-1436
15. Bann J, van der Velde ET, de Bruin GH, et al: Continuous measurement of left ventricular volume in animal and humans by conductance catheter. Circulation 1984; 70:812-823
16. Walley KR, Lewis TH, Wood LDH: Acute respiratory acidosis decreases left ventricular contractility but increases cardiac output in dogs. Circ Res 1990; 67:628-635
17. Herbertson MJ, Werner HA, Russell JA, et al: Myocardial oxygen extraction ratio is decreased during endotoxemia in pigs. J Appl Physiol 1995; 79:479-486
18. Holland BS, DiPonzio Copenhaver M: An improved sequentially rejective Bonferroni test procedure. Biometrics 1987; 43:417-423
19. Bone RC: Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992; 20:884-890
20. Braquet P, Touqui L, Shen TS, et al: Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39:97-145
21. Koltai M, Hosford D, Braquet P: Role of platelet-activating factor and cytokines in microvascular tissue injury. J Lab Clin Med 1992; 119:461-466
22. Qi M, Jones SB: Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock 1990; 32:153-163
23. Dobrowsky RT, Voyksner RD, Olson NC: Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol 1991; 260:H1455-H1465
24. Dhainaut J-FA, Tenaillon A, Le Tulzo Y, et al: Platelet-activating receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720-1728
25. Kenzora JL, Perez JE, Bergmann SR, et al: Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest 1984; 74:1193-1203
26. Piper PJ, Stewart AG: Antagonism of vasoconstriction induced by platelet-activating factor in guinea pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol 1987; 90:687-692
27. Saeki S, Masugi F, Ogihara T, et al: Effects of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine (platelet-activating factor) on cardiac function in perfused guinea-pig heart. Life Sci 1985; 37: 325-329
28. Terashita Z, Imura Y, Nishikawa K, et al: Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol 109:257-263
29. Yamanaka S, Iwao H, Yukimura T, et al: Effect of the platelet-activating factor antagonist, TCV-309, and the cyclooxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol 1993; 110:1501-1507
30. Kawamura M, Kitayoshi T, Terashita Z, et al: Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematologic abnormality induced by endotoxin in dogs. J Lipid Mediat Cell Signal 1994; 9:255-256
31. Stahl TJ, Alden PB, Ring WS, et al: Sepsis-induced diastolic dysfunction in chronic canine peritonitis. Am J Physiol 1990; 258:H625-633
32. Fuerstein G, Boyd LM, Ezra D, et al: Effects of platelet activating factor on coronary circulation of the domestic pig. Am J Physiol 1983; 246:H466-H471
33. Handley DA, Lee ML, Saunders RN: Evidence for a direct effect on vascular permeability of platelet-activating factor-induced hemoconcentration in the guinea pig. Thromb Haemost 1985; 54: 756-759
34. Laine GA, Allen SJ: Left ventricular myocardial edema. Circ Res 1991; 68: 1713-1721
35. Feuerstein G, Hallenbeck JM: Prostaglandins, leukotrienes, and platelet-activating factor in shock. Annu Rev Pharmacol Toxicol 1987; 27:301-313
36. Karasawa A, Rochester JA, Lefer AM: Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock. Methods Find Exp Clin Pharmacol 1990; 12:231-237
37. Stahl GL, Bitterman H, Terashita Z, et al: Salutary consequences of blockade of platelet activating factor in hemorrhagic shock. Eur J Pharmacol 1988; 149:233-240
38. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832
39. Finkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
40. Goddard CM, Allard MF, Hogg JC, et al: Prolonged leukocyte transit time in coronary microcirculation of endotoxemic pigs. Am J Physiol 1995; 269: H1389-H1397
41. Hwang SB, Lam MH, Alberts AW, et al: Biochemical and pharmacological characterization of L-659,989: An extremely potent, selective and competitive receptor antagonist of platelet-activating factor. J Pharmacol Exp Ther 1988; 246:534-541
42. Ponpipom MM, Hwang SB, Doebber TW, et al: (±)-Trans-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl) tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist. Biochem Biophys Res Commun 1988; 150:1213-1220